

## Case Study 2:

**A need in the pharmaceutical industry for new and improved therapeutic and diagnostic antibody-based reagents, to provide better health outcomes for patients.**

### Situation:

As monoclonal and recombinant antibodies become increasingly accessible to the clinic for treating a range of disease states including cancer, it is becoming necessary for these reagents to be optimised for use in humans and also to maximise their effectiveness. A technology to enable this process needed to be developed and taken to market.

### Approach (through Diagnostics CRC):

Technologies and expertise in the UK, Germany and Australia were identified and harnessed, and funding to support the team secured. IP was protected. Investment funding was then secured in order to develop the technology into a commercially viable process. The investment was used to establish a start-up company for this purpose.

### Result:

The start-up company – EvoGenix Ltd. - which successfully developed the commercial process, went to IPO and then merged with Peptech to form Arana Therapeutics. Arana has now been acquired by global pharmaceutical company Cephalon (US).

